Hot Pursuit     20-Sep-23
Caplin Point's subsidiary gets US FDA approval for blood pressure restoration drug
Caplin Point Laboratories informed that Caplin Steriles has been granted final approval from the United States Food and Drug Administration (US FDA) for its abbreviated new drug application (ANDA) Norepinephrine Bitartrate injection.

The said injection is a generic therapeutic equivalent version of (RLD), LEVOPHED injection of Hospira Inc.

Norepinephrine Bitartrate Injection is used for restoration of blood pressure in adult patients with acute hypotensive states.

According to IQVIATM (IMS Health), Norepinephrine Bitartrate injection USP had US sales of approximately $40 million for the 12-month period ending June 2023.

Caplin Steriles, a subsidiary of Caplin Point Laboratories, is a niche sterile product manufacturing company that is approved by several regulatory agencies such as US FDA, EU-GMP and ANVISA. Caplin Steriles has developed and filed 31 ANDAs in USA on its own and with partners, with 24 approvals so far. The company is also working on a portfolio of 40+ simple and complex injectable and ophthalmic products that it intends to file over the next 4 years.

Caplin Point Laboratories is engaged in the business of pharmaceuticals - producing, developing and marketing wide range of generic formulations and branded products and exporting to overseas market.

The company's consolidated net profit jumped 29.2% to Rs 102.11 crore in Q4 FY23 as compared with Rs 79.06 crore in Q4 FY22. Net sales rose 14.8% year on year to Rs 389.28 crore in Q4 FY23 over Q4 FY22.

The scrip shed 0.70% to currently trade at Rs 1034.40 on the BSE.

Previous News
  Caplin Point Laboratories consolidated net profit rises 19.08% in the March 2024 quarter
 ( Results - Announcements 16-May-24   15:05 )
  Board of Caplin Point Laboratories recommends Interim Dividend
 ( Corporate News - 16-May-24   14:24 )
  Volumes spurt at Caplin Point Laboratories Ltd counter
 ( Hot Pursuit - 19-Aug-24   14:30 )
  Caplin Point Laboratories schedules board meeting
 ( Corporate News - 28-Jan-23   16:41 )
  Caplin Steriles receives USFDA approval for Prochlorperazine Edisylate Injection
 ( Corporate News - 23-Apr-21   13:03 )
  Caplin Steriles' Gummidipoondi unit undergoes USFDA inspection
 ( Corporate News - 01-Jun-23   19:42 )
  Caplin Steriles receives EIR from USFDA for its unit near Chennai
 ( Corporate News - 04-Sep-23   13:56 )
  Caplin Point Laboratories to conduct board meeting
 ( Corporate News - 01-Aug-23   10:46 )
  Caplin Point Laboratories allots 1000 equity shares under ESOP
 ( Corporate News - 28-Sep-23   19:29 )
  Caplin Point Laboratories consolidated net profit rises 27.78% in the December 2019 quarter
 ( Results - Announcements 05-Feb-20   14:59 )
  Caplin Point Laboratories standalone net profit declines 30.08% in the June 2020 quarter
 ( Results - Announcements 10-Aug-20   12:58 )
Other Stories
  Macrotech Developers pre-sales jumps 21% YoY in Q2 FY25
  05-Oct-24   09:04
  UCO Bank’s total advances jump 19% YoY in Q2 FY25
  04-Oct-24   15:15
  Vakrangee Ltd leads losers in 'A' group
  04-Oct-24   15:00
  Kamdhenu Ventures Ltd leads losers in 'B' group
  04-Oct-24   14:45
  GRSE bags Rs 226-cr LoA from West Bengal Govt
  04-Oct-24   14:40
  Volumes soar at Avenue Supermarts Ltd counter
  04-Oct-24   14:30
  Real Estate stocks edge lower
  04-Oct-24   14:00
  Auto stocks edge lower
  04-Oct-24   14:00
  Utilties stocks edge lower
  04-Oct-24   14:00
  HDFC Bank Ltd down for fifth straight session
  04-Oct-24   13:35
Back Top